Nilotinib interferes with cell cycle, ABC transporters and JAK-STAT signaling pathway in CD34+/lin- cells of patients with chronic phase chronic myeloid leukemia after 12 months of treatment

Alessandra Trojani1*, Ester Pungolino1, Alessandra Dal Molin2*, Milena Lodola1, Giuseppe Rossi3, Mariella D’Adda3, Alessandra Peregò4, Chiara Elena5, Mauro Turrini6, Lorenza Borin7, Cristina Bucelli8, Simona Malato9, Maria Cristina Carraro10, Francesca Spina11, Maria Luisa Latargia12, Salvatore Artale13, Pierangelo Spedini14, Michela Anghilieri15, Barbara Di Camillo16, Giacomo Baruzzo16, Gabriella De Canal16, Alessandra Iurlo2*, Enrica Morra17, Roberto Cairoi1

1 Division of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, 2 Department of Information Engineering, University of Padova, Padova, Italy, 3 Department of Hematology, ASST Spedali Civili, Brescia, Italy, 4 Internal Medicine-Haematology, Desio Hospital, Desio, Italy, 5 Hematology Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy, 6 Division of Hematology, Department of Internal Medicine, Valduce Hospital, Como, Italy, 7 Hematology Division, San Gerardo Hospital, Monza, Italy, 8 Hematology Division, Foundation IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy, 9 Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milano, Italy, 10 Hematology and Transfusion Medicine, Sacco Hospital, Milano, Italy, 11 Division of Hematology–Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Italy, 12 ASST Valle Olfona Ospedale di Circolo, Busto Arsizio, Italy, 13 ASST Valle Olfona Sant’Antonio Abate, Gallarate, Italy, 14 Division of Hematology, Hospital of Cremona, Cremona, Italy, 15 ASST Lecco, Lecco, Italy, 16 Pathology Department, Cytogenetics, ASST Grande Ospedale Metropolitano Niguarda, Milano, Italy, 17 Executive Committee, Rete Ematologia Lombarda, Italy

These authors contributed equally to this work.

* alessandra.trojani@ospedaleniguarda.it

Abstract

Chronic myeloid leukemia (CML) is characterized by the constitutive tyrosine kinase activity of the oncoprotein BCR-ABL1 in myeloid progenitor cells that activates multiple signal transduction pathways leading to the leukemic phenotype. The tyrosine-kinase inhibitor (TKI) nilotinib inhibits the tyrosine kinase activity of BCR-ABL1 in CML patients. Despite the success of nilotinib treatment in patients with chronic-phase (CP) CML, a population of Philadelphia-positive (Ph+) quiescent stem cells escapes the drug activity and can lead to drug resistance. The molecular mechanism by which these quiescent cells remain insensitive is poorly understood. The aim of this study was to compare the gene expression profiling (GEP) of bone marrow (BM) CD34+/lin- cells from CP-CML patients at diagnosis and after 12 months of nilotinib treatment by microarray, in order to identify gene expression changes and the dysregulation of pathways due to nilotinib action. We selected BM CD34+/lin- cells from 78 CP-CML patients at diagnosis and after 12 months of first-line nilotinib therapy and microarray analysis was performed. GEP bioinformatic analyses identified 2,959 differently expressed probes and functional clustering determined some significantly enriched
pathways between diagnosis and 12 months of nilotinib treatment. Among these pathways, we observed the under expression of 26 genes encoding proteins belonging to the cell cycle after 12 months of nilotinib treatment which led to the up-regulation of chromosome replication, cell proliferation, DNA replication, and DNA damage checkpoint at diagnosis. We demonstrated the under expression of the ATP-binding cassette (ABC) transporters ABCC4, ABCC5, and ABCD3 encoding proteins which pumped drugs out of the cells after 12 months of nilotinib. Moreover, GEP data demonstrated the deregulation of genes involved in the JAK-STAT signaling pathway. The down-regulation of JAK2, IL7, STAM, PIK3CA, PTPN11, RAF1, and SOS1 key genes after 12 months of nilotinib could demonstrate the up-regulation of cell cycle, proliferation and differentiation via MAPK and PI3K-AKT signaling pathways at diagnosis.

Introduction

CML results from unfaithful repaired DNA damage in a hematopoietic stem cell, but specific features of leukemic stem cells (LSCs) have not yet been fully understood. Several studies demonstrated that LSCs show a strong resistance to therapies in TKI-treated CML patients due to their ability to activate specific signaling biological pathways [1]. Although nilotinib is highly effective in the treatment of CML, multiple clinical trials showed that some patients could become refractory and develop drug resistance [2]. Therapeutic strategies aiming for a cure of CML will require full eradication of Ph+ CML stem cells. Previous studies demonstrated that the aberrant regulation of pathways involved in the self-renewal of stem cells is implicated in cancer [3]. Identifying such pathways and trying to exploit them therapeutically is important to achieve CML-LSC eradication and disease cure [4]. Altered cell cycle checkpoints and a low intracellular concentration of TKIs are among those mechanisms that can lead to drug resistance in CML stem cells [5].

Previous studies demonstrated an increased expression of BCR-ABL1 oncogenic fusion protein-kinase and the deregulation of cell cycle proteins that induced DNA damage in CML cells [6]. These findings highlighted the properties of LSCs which become insensitive and resilient to TKI treatments in the bone marrow niche [7]. In addition, stromal cells play an important role in the survival of LSCs inducing cell cycle arrest and promote cellular quiescence in marginal environments even after TKI therapies [1].

The ABC transporters represent the most abundant transmembrane protein family encoded in the human genome. These membrane proteins transport drugs/substances across the cell membrane by ATP hydrolysis, and their physiological role as a mechanism of defense against xenobiotics has been investigated in CML [8, 9]. An altered regulation of ABC transporter proteins induced multi drug resistance (MDR) in different types of cancer cells [10]. In particular, the over expression of specific ABC transporter proteins can promote drug resistance and the development of malignancy in CML CD34+ population [10]. Indeed, Porro et al, showed that high levels of c-MYC were associated with an increased expression of some members of ABC genes (including ABCC4) which were involved in drug resistance in promyeloid leukemia cells [11].

The MDR phenotype may arise not only through the efflux of ABC transporters, but also through several other mechanisms such as pathways involved in the cell growth and survival of LSCs.

Funding: Novartis funded reagents and materials for the experiments, and provided nilotinib for this study. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. There was no additional external funding received for this study.

Competing interests: The authors have declared that non-financial competing interests exist. Novartis funded reagents and materials for the experiments in our laboratory, and provided nilotinib for this study. Novartis had no role in study design, data collection, analysis and interpretation, decision to publish or preparation of the manuscript. This does not alter our adherence to PLOS ONE policies on sharing data and materials. There was no additional external funding received for this study.
In order to identify pathways which contribute to the LSCs survival, several investigations have identified JAK2 as a putative target for CML. Hematopoietic growth factors (HGFs) bind to specific cell surface receptors in the JAK2-STAT5 cell signaling pathway. Following the HGFs binding, STAT5 is phosphorylated by JAK2 protein within the nucleus. JAK2-STAT5 signaling is involved in the signaling network downstream of BCR-ABL1, playing a crucial role in the leukemogenesis in CML cells [12]. Recently, the existence of a JAK2/BCR-ABL1 protein complex, which helps to stabilize BCR/ABL1 kinase activity, has been demonstrated [13]. Gallipoli et al. concluded that the JAK2/STAT5 signaling pathway is an important therapeutic target in CML stem/progenitor cells, and that JAK2/STAT5 inhibition by nilotinib and ruxolitinib might contribute to obtain disease eradication [12]. Clinical studies combining ruxolitinib and TKIs in CML are ongoing in an attempt to eliminate the leukemic stem cell population (EudraCT: NCT01702064).

Gene expression profiling studies have been performed to identify biomarkers predictive of TKI failure [14–16]. In particular, analyses on CML CD34+ cells have revealed that some pathways were consistently deregulated in TKI non-responding patients [1].

The PhilosoPhi34 (EudraCT: 2012-005062-34) study aimed to verify the clearance of BM CD34+/lin− Ph+ cells in CML patients after 3, 6 and 12 months of nilotinib treatment. We investigated the transcriptome profiles and the consequent deregulation of genes and pathways in CD34+/lin− cells from 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment by microarray analysis. We determined the deregulation of the cell cycle, the membrane drug-transporters and the JAK-STAT signaling pathway to provide new insight into the action of nilotinib in CP-CML patients.

Materials and methods

Patients

The PhilosoPhi34 study, which included 15 centers in Italy, collected samples from consenting patients on behalf of the Rete Ematologica Lombarda (REL). The participants provided their written consent to participate in this study. The study was approved by the Ethics Committee ASST Grande Ospedale Metropolitano Niguarda (Milan, Italy) and the following local Ethics Committees of the participants centers (Lombardia, Italy): EC ASST Spedali Civili Brescia, EC Desio Hospital, EC IRCCS Policlinico San Matteo (Pavia), EC Valduce Hospital (Como), EC Monza Brianza, EC IRCCS Ca’ Granda Ospedale Maggiore Policlinico (Milan), EC San Raffaele Scientific Institute (Milan), EC Sacco Hospital (Milan), EC IRCCS Istituto Nazionale dei Tumori (Milan), EC Valle Olona Ospedale di Circolo (Busto Arsizio), EC ASST Valle Olona Sant’Antonio Abate (Gallarate), EC Hospital of Cremona, and EC ASST Lecco. In this study, we enrolled 87 CP-CML patients [17]. Patients received first-line therapy with nilotinib 300 mg BID.

Isolation of BM CD34+/lin− cells using immunomagnetic beads

We collected BM samples from 87 patients at diagnosis. In addition, we collected BM samples after 3, 6 and 12 months of nilotinib therapy [17]. 80/87 patients were examined after 12 months of nilotinib. Among these 80 patients, only one relapsed at 12 months. Mononuclear cells (MNCs) from the bone marrow (BM) blood samples (range, 1–25 ml) of 80 CML patients were isolated using Ficoll density gradient centrifugation at 800 rpm for 20 minutes. Immediately afterwards, we selected BM CD34+/lin− cells using Diamond CD34 Isolation kit and autoMACs Pro separator (Miltenyi Biotec, Bologna, Italy) according to the manufacturer’s instructions (Miltenyi Biotec). Briefly, we labeled BM MNCs with a mix of biotin-conjugated antibodies against lineage-specific antigens. Immediately afterwards, these cells were labeled
with Anti-Biotin Microbeads. We selected the lineage-negative stem and progenitor cells by the depletion of the magnetically labeled cells. BM CD34+/lin- cells were obtained from the lineage-negative stem and progenitor cells using CD34 Microbeads (Miltenyi Biotec). The purity of isolated BM CD34+/lin- cells was detected by flow cytometry.

The methods were described in http://dx.doi.org/10.17504/protocols.io.yncfvaw, and showed in our previous study [18].

**FISH**

Standard FISH tests were performed on isolated BM CD34+/lin- cells for 87 patients at diagnosis and for 80/87 patients after 3, 6 and 12 months of nilotinib treatment. For each patient, a small sample of selected CD34+/lin- cells (containing at least $10^6$ cells fixed in Carnoy’s solution) was analyzed by FISH using standard method [18]. Samples were co-hybridized to XL BCR/ABL1 plus Translocation/Dual Fusion Probe (MetaSystems, Milan, Italy) on Thermo-Brite Statspin Model (Leica Biosystems, US). FISH analyses were performed using fluorescence microscope Axioskop 2 (Carl Zeiss Microimaging GmbH, Göttingen, Germany), equipped with a UV 100-W lamp (Osram, Augsburg, Germany), ProgRes MF CCD camera (Jenoptik AG, Jena, Germany), and ISIS System Software (MetaSystems Hard & Software, Altlussheim, Germany).

**Fine modulo.**  At least, 200 interphase nuclei were counted from each suitable specimen (optimum: 300 nuclei). Each available interphase nucleus was read even in sub-optimal specimens. FISH analyses were performed as described by Trojani et al [18], and in http://dx.doi.org/10.17504/protocols.io.yncfvaw.

**Cell cryopreservation and RNA extraction**

Selected BM CD34+/lin- cells of 80 CP-CML patients were resuspended in 50 μl of RNAlater (Thermo Fisher Scientific, Milano, Italy) and stored at -20°C until RNA extraction was performed as previously described [18].

Total RNA was isolated from the BM CD34+/lin- cells stored in RNAlater using MagMAX 96 Total RNA Isolation Kit (Thermo Fisher Scientific) [18], according to the manufacturer’s instructions. The quality and the yield of the extracted RNA were measured using Nanodrop (Thermo Fisher Scientific) (see http://dx.doi.org/10.17504/protocols.io.yncfvaw).

**GEP experiments**

Microarray experiments were performed on the BM CD34+/lin- cells of 80 CP-CML patients at diagnosis as well as those who had undergone 12 months of nilotinib treatment. We prepared cDNA starting from the previously extracted RNA (50 ng) using Ovation Pico WTA System V2 kit (NuGEN) and Encore Biotin Module Kit (NuGEN) following the manufacturer’s instructions.

cDNA was hybridized to Affymetrix HTA 2.0 using the Gene Chip platform (Affymetrix, Santa Clara, Ca, USA) and signals were scanned by Affymetrix Gene Chip Scanner 3000 according to the manufacturer’s instructions as described in http://dx.doi.org/10.17504/protocols.io.yncfvaw, and in our previous manuscript [18].

**Bioinformatic analyses of GEP data**

The preprocessing of microarray raw data was performed using R software version 3.4.2 [19]. The Affymetrix HTA 2.0 probes were initially summarized into probe sets specific for a given gene using function RMA [20] of R package oligo [21], downloaded from Bioconductor.
Principal component analysis (PCA) has been performed using `prcomp` function of package `stats` version 3.4.2 [19]. MvA plots were generated using custom scripts. MvA plots show the relationship among the average log intensity of the gene expression (A value) and the log of intensity ratio (M value) between two samples. PCA and MvA plots were examined before and after microarray preprocessing as a quality checking procedure. PCA plots revealed the presence of batch effects due to the different protocols used for performing RNA extraction and GEP experiments. Batch effects have been corrected using function `ComBat` [22] of R package `sva` [23]. MvA plots showed the presence of bias in the distribution of intensities among samples, then data was normalized using function `normalize.quantiles` of R package `preprocessCore` [24].

The differential expression analysis was performed on the samples at 12 months vs. diagnosis using the two-classes SAM test [25], implemented in the homonym function in R package `samr` [25]. Benjamini-Hochberg procedure was applied to control the False Discovery Rate (FDR) and a cut-off value of 0.05 was applied to select for significant differential expression [26].

Functional clustering was performed on significant differentially expressed genes using online tool DAVID (https://david.ncifcrf.gov/) [27, 28], to classify them into functional groups based on their annotation term co-occurrence. For this analysis, 1,723 protein coding genes which have a unique EntrezID in the “Affymetrix NetAffx” annotation were used (HTA 2.0 Transcript Cluster Annotations, Release 36, 7/6/16). Groups that resulted significantly enriched were selected based on FDR value below 0.05 [29], (see http://dx.doi.org/10.17504/protocols.io.yncfvaw).

Results

FISH

At diagnosis, FISH analysis detected BM CD34+/lin- Ph+ cells in all 87 CP-CML patients. At 12 months, we could analyze 80/87 patients [17]. 79/80 patients were evaluable because they achieved at least a complete cytogenetic response whereas 1/80 patient relapsed at 12 months. No Ph+ nuclei were detected in 79/79 patients [17].

Purity of selected cells, quality and yield of total RNA

The purity of BM CD34+/lin- cells was > 97% as determined by flow cytometry (S1 Appendix). The purity of the extracted RNA was in the range of 1.7–1.8, determined by absorbance ratios of A(260)/A(280) using a NanoDrop Spectrophotometer (Thermo Fisher Scientific). The total RNA concentration isolated from 100,000 BM CD34+/lin- cells was about 300 ng.

Preprocessing of HTA 2.0 arrays of BM CD34+/lin- cells of CP-CML patients at diagnosis and after 12 months of nilotinib treatment

We performed the preprocessing and correction for batch effects for samples of 80 patients at diagnosis and after 12 months of nilotinib treatment. We conducted the analyses on 78 subjects. Due to experimental issues, two patients were not considered for differential expression analysis, as the microarray CEL files of the 12 months samples were corrupted and missed probe intensities for most of the probes. After correction for batch effects and normalization, no more batch effects or residual systematic differences were observed in all the 156 arrays.
Identification of genes and pathways deregulated between BM CD34+/lin-cells of CP-CML patients at diagnosis vs. 12 months of nilotinib treatment

The differential expression analysis detected 2,959 probes (corresponding to 2,726 unique genes and 1,740 unique gene symbols) differently expressed (DE) between 78 patients at diagnosis compared to 12 months of nilotinib treatment (S1 Table). Among the unique genes, 1,868 genes were annotated as “protein coding” and 858 as “non-coding” in the “Affymetrix NetAffx” annotation (HTA 2.0 Transcript Cluster Annotations, Release 36, 7/6/16). Most of non-coding DE genes (364 genes) consisted of long non-coding RNAs, while the remaining genes were annotated as snoRNAs, miRNAs, piRNAs, miscRNAs, tRNAs and rRNAs.

The functional clustering analysis revealed interesting functional groups of genes, involved in cell cycle, ATP-binding, and JAK-STAT pathway (Table 1 and S2 Table).

Up-regulation of 26 genes of the Cell Cycle (G1, S, G2 and M phases), DNA damage and repair at diagnosis

Functional enrichment analysis demonstrated that 26/124 genes encoding proteins that belong to the cell cycle pathway were significantly over expressed at diagnosis compared to 12 months of nilotinib (Tables 1 and 2, Fig 1A). ORC5, ORC2, ORC4 (Origin Recognition Complex), MCM3, MCM6 (Mini-Chromosome Maintenance complex) and HDAC2 encoding proteins that belong to G1 phase of the cell cycle (Cell cycle control of Chromosome replication), were up-regulated at diagnosis. We demonstrated that CCNA2, CDK7, CDC6, DBF4, ORC5, ORC2, ORC4, MCM3, and MCM6 (S phase of the cell cycle) were over expressed at diagnosis. GEP results showed that CCNA2, CCNB1, WEE1, PRKDC, ATM, MDM2 (G2 phase of the cell cycle) as well as TTK, MAD2L1, BUB3, BUB1, ANAPC1, ANAPC4, ANAPC7, CDC27, SMC3, YWHAE, and YWHAZ (M phase of the cell cycle) were over expressed at diagnosis compared to 12 months of nilotinib.

Over expression of ATP-binding ABC transporters genes in CD34+/lin-cells at diagnosis

GEP data demonstrated that ABCC4, ABCC5 and ABCD3 genes were significantly up-regulated at diagnosis (Tables 1 and 3, Fig 1B). We previously demonstrated the over expression of ABCC5 at diagnosis vs. 12 months of nilotinib treatment in 30 CP-CML patients [18].

Activation of JAK-STAT signaling pathway at diagnosis vs. 12 months of nilotinib

We analyzed JAK-STAT signaling pathway that is made up of 155 genes (Kegg Pathway Database). This pathway was deregulated in CD34+/lin- cells at diagnosis vs. 12 months of nilotinib treatment. SOS1, PIK3CA, RAF1, IL7, JAK2, STAM, and PTPN11 were up-regulated whereas IL22RA was down-regulated at diagnosis (Tables 1 and 4, Fig 1C).

Discussion

The resistance to TKIs remains one of the major causes of treatment failure and patient death in CML [30]. A better understanding of the molecular biology of LSCs is crucial to develop more effective treatments for advanced CML and prevent drug resistance [1].

To the best of our knowledge, we hereby report for the first time the results of a wide transcriptome analysis of BM CD34+/lin- cells of 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment. We found 2,959 probes differently expressed at diagnosis compared to 12 months of nilotinib treatment. In particular, we focused on genes which are over expressed
at diagnosis and which play a crucial role in the cell cycle, ATP-binding ABC transporters and JAK-STAT signaling pathway (Fig 1).

Gene expression and proteomic profile studies of CML LSCs drew attention to specific gene pathways that could represent both prognostic indicators as well as new targets for therapy that might eventually overcome resistance to the BCR-ABL TKIs [31, 32].

Table 1. Genes with significant differential expression in BM CD34+/lin- cells from 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment.

| Gene Symbol | Fold Change | Adjusted p-value | KEGG Pathway |
|-------------|-------------|------------------|--------------|
| ANAPC1      | 1.23        | 0.01             | CELL CYCLE AND MITOSIS |
| ANAPC4      | 1.20        | 0.01             | CELL CYCLE AND MITOSIS |
| ANAPC7      | 1.16        | 0.04             | CELL CYCLE AND MITOSIS |
| ATM         | 1.24        | 0.01             | CELL CYCLE AND MITOSIS |
| BUB1        | 1.16        | 0.04             | CELL CYCLE AND MITOSIS |
| BUB3        | 1.23        | 0.02             | CELL CYCLE AND MITOSIS |
| CCNA2       | 1.29        | 0.01             | CELL CYCLE AND MITOSIS |
| CCNB1       | 1.26        | 0.02             | CELL CYCLE AND MITOSIS |
| CDC27       | 1.27        | 0.01             | CELL CYCLE AND MITOSIS |
| CDC6        | 1.21        | 0.02             | CELL CYCLE AND MITOSIS |
| CDK7        | 1.17        | 0.04             | CELL CYCLE AND MITOSIS |
| DBF4        | 1.19        | 0.02             | CELL CYCLE AND MITOSIS |
| HADC2       | 1.33        | 0.02             | CELL CYCLE AND MITOSIS |
| MAD2L1      | 1.27        | 0.01             | CELL CYCLE AND MITOSIS |
| MCM3        | 1.19        | 0.02             | CELL CYCLE AND MITOSIS |
| MCM6        | 1.25        | 0.03             | CELL CYCLE AND MITOSIS |
| MDM2        | 1.26        | 0.02             | CELL CYCLE AND MITOSIS |
| ORC2        | 1.31        | 0.01             | CELL CYCLE AND MITOSIS |
| ORC4        | 1.19        | 0.03             | CELL CYCLE AND MITOSIS |
| ORC5        | 1.17        | 0.02             | CELL CYCLE AND MITOSIS |
| PRKDC       | 1.27        | 0.01             | CELL CYCLE AND MITOSIS |
| SMC3        | 1.26        | 0.02             | CELL CYCLE AND MITOSIS |
| TTK         | 1.24        | 0.02             | CELL CYCLE AND MITOSIS |
| WEE1        | 1.31        | 0.01             | CELL CYCLE AND MITOSIS |
| YWHAE       | 1.38        | 0.01             | CELL CYCLE AND MITOSIS |
| YWHAZ       | 1.36        | 0.05             | CELL CYCLE AND MITOSIS |
| ABCD3       | 1.19        | 0.03             | ABC TRANSPORTERS |
| ABCC5       | 1.09        | 0.04             | ABC TRANSPORTERS |
| ABCC4       | 1.21        | 0.01             | ABC TRANSPORTERS |
| IL22RA1     | -1.13       | 0.02             | JAK-STAT |
| SOS1        | 1.32        | 0.01             | JAK-STAT |
| PIK3CA      | 1.24        | 0.01             | JAK-STAT |
| RAF1        | 1.11        | 0.03             | JAK-STAT |
| IL7         | 1.16        | 0.03             | JAK-STAT |
| JAK2        | 1.21        | 0.02             | JAK-STAT |
| STAM        | 1.29        | 0.01             | JAK-STAT |
| PTPN11      | 1.18        | 0.03             | JAK-STAT |

* Official gene symbols.
* Fold changes of gene expression (12 months vs. diagnosis).
* P-value adjusted according to Benjamini-Hochberg false discovery rate.
* KEGG pathway name.

https://doi.org/10.1371/journal.pone.0218444.t001
The alteration of different signaling pathways such as cell cycle, JAK-STAT, and the deregulation of ABC drug efflux transporters can promote the development of growth and survival of CML progenitor and stem cells [1]. Some authors showed that several genes encoding proteins involved in the cell cycle and chromosome segregation were up-regulated in CML LSCs [1]. We demonstrated that 26 genes representing phases of the cell cycle (G1, S, G2 and M), were over expressed at diagnosis compared to 12 months of nilotinib treatment in 78 CP-CML patients (Tables 1 and 2). The integrity of signaling pathways involved in cell cycle arrest, chromatin remodeling and DNA repair are critical to maintain the fidelity of replicated DNA. Mancini et al, demonstrated that normal cells repaired damaged DNA during G1 arrest whereas leukemic cells often had a deficient G1/S checkpoint and this depended on a functional G2/M checkpoint for DNA repair (Mancini M. et al. Blood. 2017; Abs. Suppl1 130:1588).

Among the 26 deregulated genes, we found that ORC5, ORC2, ORC4, MCM3, MCM6, and HDAC2 controlled G1 phase as well chromosome replication. The up-regulation of these genes was associated with the initiation of DNA replication [33]. Notably, some studies demonstrated that HDAC inhibitors treatment represented an effective strategy to target LSCs in CP-CML patients receiving tyrosine kinase inhibitors [34, 35].

### Table 2. Genes of the Cell cycle and Mitosis pathway with significant differential expression in BM CD34+/lin-cells from 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment.

| Gene Symbol | Fold Change | Adjusted p-value |
|-------------|-------------|------------------|
| ANAPC1      | 1.23        | 0.01             |
| ANAPC4      | 1.20        | 0.01             |
| ANAPC7      | 1.16        | 0.04             |
| ATM         | 1.24        | 0.01             |
| BUB1        | 1.16        | 0.04             |
| BUB3        | 1.23        | 0.02             |
| CCNA2       | 1.29        | 0.01             |
| CCNB1       | 1.26        | 0.02             |
| CDC27       | 1.27        | 0.01             |
| CDC6        | 1.21        | 0.02             |
| CDK7        | 1.17        | 0.04             |
| DBF4        | 1.19        | 0.02             |
| HDAC2       | 1.33        | 0.02             |
| MAD2L1      | 1.27        | 0.01             |
| MCM3        | 1.19        | 0.02             |
| MCM6        | 1.25        | 0.03             |
| MDM2        | 1.26        | 0.02             |
| ORC2        | 1.31        | 0.01             |
| ORC4        | 1.19        | 0.03             |
| ORC5        | 1.17        | 0.02             |
| PRKDC       | 1.27        | 0.01             |
| SMC3        | 1.26        | 0.02             |
| TTK         | 1.24        | 0.02             |
| WEE1        | 1.31        | 0.01             |
| YWHAE       | 1.38        | 0.01             |
| YWHAZ       | 1.36        | 0.05             |

*a Official gene symbols.

*b Fold changes of gene expression (12 months vs. diagnosis).

*c P-value adjusted according to Benjamini-Hochberg false discovery rate.

https://doi.org/10.1371/journal.pone.0218444.t002
Our GEP results demonstrated that genes encoding proteins involved in the S phase of cell cycle (CCNA2, CDK7, CDC6, DFB4, MCM3, and MCM6) were down-regulated after 12 months of nilotinib. Previous studies showed that these genes might promote the cell proliferation and DNA replication in CML CD34+/lin- cells at diagnosis [15, 36, 37].

We showed that CCNA2, CCNB1, WEE1, PRKDC, ATM and MDM2 (G2 phase) were down-regulated after 12 months of nilotinib. Notably, the study by Reynaud et al, demonstrated the over expression of CCNA2 and CCNB1 in CML-LSCs of transgenic mice [38].

Our study demonstrated that TTK, MAD2L1, BUB3, BUB1, ANAPC1, ANAPC4, ANAPC7, CDC27, SMC3, YWHAE, and YWHAZ (mitosis) were over expressed at diagnosis. In particular, TTK and MAD2L1 might increase cell proliferation in CML CD34+/lin- cells at diagnosis, and some researchers demonstrated that they were over expressed in CML leukemic stem cells compared to the same cell counterpart from normal subjects [15]. Moreover, previous studies

Table 3. Genes of the ATP-binding cassette (ABC) pathway with significant differential expression in BM CD34+/lin- cells from 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment.

| Gene Symbol | Fold Change | Adjusted p-value |
|-------------|-------------|-----------------|
| ABCD3       | 1.19        | 0.03            |
| ABCC5       | 1.09        | 0.04            |
| ABCC4       | 1.21        | 0.01            |

a Official gene symbols.
b Fold changes of gene expression (12 months vs. diagnosis).
c P-value adjusted according to Benjamini-Hochberg false discovery rate.

https://doi.org/10.1371/journal.pone.0218444.t003
showed the over expression of the mitotic checkpoint genes BUB1 and BUB2 in several solid
tumors [39–41].

In conclusion, we can reasonably speculate that all the 26 genes over expressed at diagnosis
led to the up-regulation of the cell cycle in CML CD34+/lin- cells at diagnosis increasing their
survival with respect to 12 months of nilotinib treatment.

Our results showed that ABCC5, ABCC4 and ABCD3 were significantly under expressed in
CP-CML patients after 12 months of nilotinib treatment compared to diagnosis [18]. Previous
studies demonstrated that drug transporters, particularly ATP-binding cassette (ABC) trans-
porters, played a critical role in the intracellular levels of TKI and primary resistance [10].
Indeed, 48 genes represent the ABC transporters family (Kegg Pathway Database), and the up-
regulation of some of them can lead to MDR by promoting the efflux of drugs out of the cells
[9, 10, 11, 42]. Recent studies have investigated ABCC4 and ABCC5 to clarify the clinical signif-
icance of their altered function and expression in MDR. In particular, Chen et al, demon-
strated that proteins encoded by ABCC4 and ABCC5 were expressed at low levels in all normal
tissues [42]. Wang et al, demonstrated that both ABCC4 and ABCC5 regulated the efflux of
purine analogues. In order to overcome the drug resistance, recent in vitro studies demon-
strated that TKIs such as nilotinib and imatinib were able to inhibit the efflux actions of ABC
transporter proteins [43–46].

Several studies on CML demonstrated JAK-STAT signaling pathway as a potential survival
mechanism of CML LSCs [4]. Recently, researchers focused on the function of the intracellular
JAK2 in the survival and proliferation of CML LSCs and its putative role as a therapeutic target
in CML [12]. The combination of JAK2 inhibitors with TKI showed to be effective against
CML cell lines and primary cells. However, further work is still required to assess the effective-
ness, toxicity and specificity of inhibitors [31, 47–49]. Some studies are ongoing to identify
other regulators of the JAK-STAT pathway and to design innovative therapeutic strategies.
Our GEP data demonstrated an average up-regulation of 7 genes (JAK2, SOS1, PIK3CA, RAF1,
IL7, STAM, and PTPN11) encoding proteins of JAK-STAT signaling pathway at diagnosis.

In addition, the JAK-STAT pathway plays a major role in the transfer of signals from cell-
membrane receptors to the nucleus [50]. The interaction between the surface receptors and
the cytokines activates JAK2 and the cascade of genes which lead to the proliferation, differen-
tiation, cell cycle and survival of LSCs. Our study identified the dysregulation of MAPK and
PI3K signaling pathways due to the over expression of PTPN11, SOS1, RAF1 and PIK3C,
respectively [51–53]. Moreover, JAK2 could promote the phosphorylation of PIK3CA via

### Table 4. Genes of the JAK-STAT pathway with significant differential expression in BM CD34+/lin- cells from 78 CP-CML patients at diagnosis vs. 12 months of nilotinib treatment.

| Gene Symbol* | Fold Changeb | Adjusted p-valuec |
|--------------|--------------|--------------------|
| IL22RA1      | -1.13        | 0.02               |
| SOS1         | 1.32         | 0.01               |
| PIK3CA       | 1.24         | 0.01               |
| RAF1         | 1.11         | 0.03               |
| IL7          | 1.16         | 0.03               |
| JAK2         | 1.21         | 0.02               |
| STAM         | 1.29         | 0.01               |
| PTPN11       | 1.18         | 0.03               |

* Official gene symbols.

b Fold changes of gene expression (12 months vs. diagnosis).

c P-value adjusted according to Benjamini-Hochberg false discovery rate.

https://doi.org/10.1371/journal.pone.0218444.t004
PI3K-AKT signaling pathway [53] that might be responsible to TKI resistance in Ph+ cell lines [54].

In summary, we identified gene expression changes in BM CD34+/lin- cells of a cohort of 78 CP-CML patients after 12 months of nilotinib therapy compared to diagnosis. The dysregulation of cell cycle and DNA repair, ABC transporters, and JAK-STAT signaling pathway after treatment with nilotinib are interesting, since previous studies highlighted the role of these pathways in CML.

We determined that the BM CD34+/lin- cells at diagnosis were all Ph-positive whereas the same cells after 12 months of nilotinib were Ph-negative by FISH analyses. We could suppose that BM CD34+/lin- cells of patients after 12 months of nilotinib were normal because of the cytogenetic results. To clarify this point, we will compare GEP of BM CD34+/lin- cells after 12 months of nilotinib with respect to the normal cell counterparts of healthy donors.

The potential suitability of the genes highlighted in our study as biomarkers in CML requires, however, further investigation to address their clinical relevance. We strongly believe that the identification of dysregulated signaling pathways in progenitor and stem cells in CML patients can significantly alter the presentation of the disease and its progression, and therefore might suggest the design of new therapeutic strategies in CML. Furthermore, the identification of pathways that might represent new drug-targets for elimination of LSCs, could improve the outcomes of CML patients.

Supporting information
S1 Appendix. A representative FACS plot of the purity of BM CD34+/lin- cells determined by flow cytometry.
(PPTX)

S1 Table. Results of the differential expression analysis on 78 CML patients at diagnosis vs. 12 months of treatment with nilotinib.
(XLSX)

S2 Table. Results of the functional clustering analysis performed with DAVID tool on differentially expressed genes.
(XLSX)

Acknowledgments
We would like to thank ASST Grande Ospedale Metropolitano Niguarda which promoted the study on behalf of REL. The authors would like to thank Dr John Welch for his proof reading.

Author Contributions
Conceptualization: Alessandra Trojani, Ester Pungolino.

Data curation: Alessandra Trojani, Alessandra Dal Molin, Milena Lodola, Barbara Di Camillo, Giacomo Baruzzo, Gabriella De Canal.

Formal analysis: Alessandra Dal Molin, Barbara Di Camillo, Giacomo Baruzzo.

Investigation: Alessandra Trojani, Milena Lodola, Gabriella De Canal.

Project administration: Ester Pungolino, Roberto Cairoli.

Resources: Ester Pungolino, Giuseppe Rossi, Mariella D’Adda, Alessandra Perego, Chiara Elena, Mauro Turrini, Lorenza Borin, Cristina Bucelli, Simona Malato, Maria Cristina
Carraro, Francesco Spina, Maria Luisa Latargia, Salvatore Artale, Pierangelo Spedini, Michela Anghilieri, Alessandra Iurlo.

Software: Alessandra Dal Molin, Barbara Di Camillo, Giacomo Baruzzo.

Supervision: Alessandra Trojani, Ester Pungolino, Enrica Morra, Roberto Cairoli.

Validation: Alessandra Trojani, Ester Pungolino, Alessandra Dal Molin, Barbara Di Camillo, Giacomo Baruzzo, Roberto Cairoli.

Writing – original draft: Alessandra Trojani, Alessandra Dal Molin, Barbara Di Camillo, Giacomo Baruzzo.

Writing – review & editing: Alessandra Trojani, Alessandra Dal Molin, Barbara Di Camillo, Giacomo Baruzzo.

References

1. Zhou H, Xu R. Leukemia stem cells: the root of chronic myeloid leukemia. Protein Cell. 2015; 6:403–12. Epub 2015 Mar 10. https://doi.org/10.1007/s13238-015-0143-7 PMID: 25749979

2. Yang K, Fu L-W. Mechanisms of resistance to BCR–ABL TKIs and the therapeutic strategies: A review Critical Reviews in Oncology/Hematology. 2015; 93:277–292.

3. Matsui WH. Cancer stem cell signaling pathways. Send to Medicine (Baltimore). 2016; 95:S8–S19. https://doi.org/10.1097/MD.0000000000004765

4. Holyoake TL, Vetrie D. The chronic myeloid leukemia stem cell: stemming the tide of persistence. Blood. 2017; 129:1595–1606. Epub 2017 Feb 3. Review. https://doi.org/10.1182/blood-2016-09-696013 PMID: 28159740

5. Quintás-Cardama A, Cortes J. Molecular biology of bcr-abl1-positive chronic myeloid leukemia. Blood. 2009; 113:1619–1630. Epub 2008 Sep 30. Review. https://doi.org/10.1182/blood-2008-03-144790 PMID: 18827185

6. Cramer K, Nieborowska-Skorska M, Kopytra M, Slupianek A, Pensioga ET, Eaves CJ, et al. BCR/ABL and other kinases from chronic myeloproliferative disorders stimulate single-strand annealing, an unfaithful DNA double-strand break repair. Cancer Res. 2008; 68:6884–6888. https://doi.org/10.1158/0008-5472.CAN-08-1101 PMID: 18757400

7. Wang A, Zhong H. Roles of the bone marrow niche in hematopoiesis, leukemogenesis, and chemotherapy resistance in acute myeloid leukemia. Hematology. 2018; 14:1–11. https://doi.org/10.1080/10245332.2018.1468064 [Epub ahead of print].

8. Ambudkar SV, Kim IW, Xia D, Sauna ZE. The A-loop, a novel conserved aromatic acid subdomain upstream of the Walker A motif in ABC transporters, is critical for ATP binding. FEBS Lett. 2006; 580:1049–1055. Epub 2005 Dec 22. Review. https://doi.org/10.1016/j.febslet.2005.12.051 PMID: 16412422

9. Giannoudis A, Davies A, Harris RJ, Lucas CM, Pirmohamed M, Clark RE. The clinical significance of ABCC3 as an imatinib transporter in chronic myeloid leukaemia. Leukemia. 2014; 28:1360–1363. Epub 2014 Jan 20. https://doi.org/10.1038/leu.2014.38 PMID: 24441286

10. Wang YJ, Zhang YK, Kathawala RJ, Chen ZS. Repositioning of tyrosine kinase inhibitors as antagonists of ATP-binding cassette transporters in anticancer drug resistance. Cancers (Basel). 2014; 6:1925–1952. https://doi.org/10.3390/cancers6041925 Review.

11. Porro A, Iraci N, Soverini S, Diolaiti D, Gherardi S, Terragna C, et al. c-MYC oncprotein dictates transcriptional profiles of ATP-binding cassette transporter genes in chronic myogenous leukaemia CD34+ hematopoietic progenitor cells. Mol Cancer Res. 2011; 9:1054–1066. Epub 2011 Jun 21. https://doi.org/10.1158/1541-7786.MCR-10-0510 PMID: 21693596

12. Gallipoli P, Cook A, Rhodes S, Hopcroft L, Wheaton H, Whetton AD, at al. JAK2/STAT5 inhibition by nilotinib with ruxolitinib contributes to the elimination of CML CD34+ cells in vitro and in vivo. Blood. 2014; 124:1492–1501. Prepublished online 2014 Jun 23. https://doi.org/10.1182/blood-2013-12-546640 PMID: 24957147

13. Chen M, Gallipoli P, DeGeer D, Sloma I, Forrest DL, Chan M, et al. Targeting primitive chronic myeloid leukemia cells by effective inhibition of a new AHI-1–BCR-ABL-JAK2 complex. J Natl Cancer Inst. 2013; 105:405–423. Epub 2013 Feb 27. https://doi.org/10.1093/jnci/djt006 PMID: 23446755

14. Singh N, Tripathi AK, Sahu DK, Mishra A, Linan M, Argente B, et al. Differential genomics and transcriptomics between tyrosine kinase inhibitor-sensitive and -resistant BCR-ABL-dependent chronic myeloid
leukemia. Oncotarget. 2018; 13:30385–30418. https://doi.org/10.18632/oncotarget.25752 eCollection 2018 Jul 13.
15. Avilés-Vázquez S, Chávez-González A, Hidalgo-Miranda A, Moreno-Lorencano D, Arriaga-Pizano L, Sandoval-Esquível MA, et al. Global gene expression profiles of hematopoietic stem and progenitor cells from patients with chronic myeloid leukemia: the effect of in vitro culture with or without imatinib. Cancer Med. 2017; 6:2942–2956. https://doi.org/10.1002/cam4.1187 Epub 2017 Oct 13.
16. Arrigoni E, Del Re M, Galimberti S, Restante G, Rolf E, Crucitta S, et al. Concise Review: Chronic myeloid leukemia: stem cell niche and response to pharmacologic treatment. Stem Cells Transl Med. 2018; 7:305–314. Epub 2018 Feb 8. https://doi.org/10.1002/stcm.17-0175 PMID: 29418079
17. Pungolino E, Rossi G, De Canal G, Trojani A, D’Adda M, Perezo G, et al. Nilotinib induced bone marrow CD34+/Lin-Ph+ cells early clearance in newly diagnosed CP-chronic myeloid leukemia. Am J Hematol. 2018; 93:E162–E164. Epub 2018 May 17. No abstract available. https://doi.org/10.1002/ajh.25106 PMID: 29633310
18. Trojani A, Pungolino E, Rossi G, D’Adda M, Lodola M, Camillo BD, et al. Wide-transcriptome analysis and cellularity of bone marrow CD34+/Lin- cells of patients with chronic-phase chronic myeloid leukemia at diagnosis vs. 12 months of first-line nilotinib treatment. Cancer Biomark. 2017; 21:41–53. https://doi.org/10.3233/CBM-170209 PMID: 29036785
19. R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria; 2017. Available from URL: http://www.R-project.org/.
20. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res. 2003; 31:e15. https://doi.org/10.1093/nar/gng015 PMID: 12582260
21. Carvalho BS, Irizarry RA. A Framework for Oligonucleotide Microarray Preprocessing. Bioinformatics. 2010; 26:2363–2367. ISSN 1367-4803. R package version 1.42.0. https://doi.org/10.1093/bioinformatics/btq431 PMID: 20688976
22. Johnson WE, Li, Rabinovic A. Adjusting batch effects in microarray data using empirical bayes methods. Biostatistics 2007; 8:118–127. https://doi.org/10.1093/biostatistics/kxm037 PMID: 16632515
23. Leek JT, Johnson WE, Parker HS, Fertig EJ, Jaffe AE, Storey JD, et al. 2018. sva: Surrogate Variable Analysis. R package version 3.22.0.
24. Bolstad B (2018). preproccessCore: A collection of pre-processing functions. R package version 1.36.0.
25. Johnson WE, Li, Rabinovic A. Adjusting batch effects in microarray data using empirical bayes methods. Biostatistics 2007; 8:118–127. https://doi.org/10.1093/biostatistics/kxm037 PMID: 16632515
26. Carvalho BS, Irizarry RA. A Framework for Oligonucleotide Microarray Preprocessing. Bioinformatics. 2010; 26:2363–2367. ISSN 1367-4803. R package version 1.42.0. https://doi.org/10.1093/bioinformatics/btq431 PMID: 20688976
27. Benjamini and Hochberg. Controlling the first discovery rate: a practical and powerful approach to multiple testing. Journal of the Royal Statistical Society. Series B (Methodological). 1995; 57:289–300.
28. Huang DW, Sherman BT, Lempicki RA. Systematic and integrative analysis of large gene lists using DAVID Bioinformatics Resources. Nature Protoc. 2009; 4:44–57.
29. Storey JD A direct approach to false discovery rates. J R Stat Soc. 2002; 3:479–498.
30. Wieczorek A, Uharek L. Management of chronic myeloid leukemia patients resistant to tyrosine kinase inhibitors treatment. Biomark Insights. 2015; 10:49–54. Published online 2016 Feb 18. https://doi.org/10.4137/BMI.S22431 PMID: 26917943
31. Sinclair A, Latif AL, Holyoake TL. Targeting survival pathways in chronic myeloid leukaemia stem cells. Br J Pharmacol. 2013; 169: 1693–1707. Published online 2013 Jul 26. https://doi.org/10.1111/bph.12183 PMID: 23517124
32. Ricciardi MR, Salvestrini V, Licchetta R, Mirabili S, Forcato M, Gugliotta G, et al. Differential proteomic profile of leukemic CD34+ progenitor cells from chronic myeloid leukemia patients. Oncotarget. 2018; 9:21758–21769. eCollection 2018 Apr 24. https://doi.org/10.18632/oncotarget.24938 PMID: 29774100
33. Duncker BP, Chesnokov IN, McConkey BJ. The origin recognition complex protein family. Genome Biol. 2009; 10:214. Published online 2009 Mar 17. https://doi.org/10.1186/gb-2009-10-3-214 PMID: 19344485
34. Zhang B, Strauss AC, Chu S, Li M, Ho Y, Shiang KD, et al. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate. Cancer Cell. Author manuscript; available in PMC 2011 May 18. Published in final edited form as: Cancer Cell. 2010; 17: 427–442. https://doi.org/10.1016/j.ccr.2010.03.011 PMID: 20478526
35. Stubbs MC, Kim W, Bariffeau M, Davis T, Vempati S, Minehart J, et al. Selective inhibition of HDAC1 and HDAC2 as a potential therapeutic option for B-ALL. Clin Cancer Res. Author manuscript; available
Gene profiling of patients with chronic myeloid leukemia at diagnosis vs. 12 months of nilotinib in PMC 2016 May Published in final edited form as: Clin Cancer Res. 2015; 21:2348–2358. Published online 2015 Feb 16. https://doi.org/10.1158/1078-0432.CCR-14-1290 PMID: 25688158

36. Wu Y, Chen C, Sun X, Shi X, Jin B, Ding K, et al. Cyclin-dependent kinase 7/9 inhibitor SNS-032 abrogates FIP1-like 1 platelet-derived growth factor receptor α and bcr-abl oncogene addiction in malignant hematologic cells. Clin Cancer Res. 2012 A; 18:1966–1978. https://doi.org/10.1158/1078-0432.CCR-11-1971 Epub 2012 Mar 23.

37. Zhang JH, He YL, Zhu R, Du W, Xiao JH. Deregulated expression of Cdc6 as BCR/ABL-dependent survival factor in chronic myeloid leukemia cells. Tumour Biol. 2017; 39:1010428317713394. https://doi.org/10.1177/1010428317713394 PMID: 28639894

38. Reynaud D, Pietras E, Barry-Holson K, Mir A, Binnewies M, Jeanne M, et al. IL-6 controls leukemic multipotent progenitor cell fate and contributes to chronic myelogenous leukemia development. Cancer Cell. 2011; 20:661–673. https://doi.org/10.1016/j.ccr.2011.01.012 PMID: 22094259

39. Kalitsis P, Earle E, Fowler KJ, Choo KH. Bub3 gene disruption in mice reveals essential mitotic spindle checkpoint function during early embryogenesis. Genes Dev. 2000; 14:2277–2282. PMC 316933. https://doi.org/10.1101/gad.827500 PMID: 10995385.

40. Yuan B, Xu Y, Woo JH, Wang Y, Bae YK, Yoon DS, et al. Increased expression of mitotic checkpoint genes in breast cancer cells with chromosomal instability. Clin Cancer Res. 2006; 12:405–410. https://doi.org/10.1158/1078-0432.CCR-05-0903 PMID: 16428479

41. Grabsch H, Takeno S, Parsons WJ, Pomjanski N, Boecking A, Gabbert HE, et al. Overexpression of the mitotic checkpoint genes BUB1, BUBR1, and BUB3 in gastric cancer-association with tumour cell proliferation. J Pathol. 2003; 200:16–22. https://doi.org/10.1002/path.1324 PMID: 12692836

42. Chen Z-S, Tiwari AK. Multidrug resistance proteins (MRPs/ABCCs) in cancer chemotherapy and genetic diseases. FEBS J. Author manuscript; available in PMC 2012 Sep 1. Published in final edited form as: FEBS J. 2011; 278:3242–3245. Published online 2011 Aug 1. https://doi.org/10.1111/j.1742-4658.2011.08235.x PMID: 21740521

43. Eadie LN, Hughes TP, White DL. ABCB1 overexpression is a key initiator of resistance to tyrosine kinase inhibitors in CML cell lines. PLoS One. 2016; 11: e0161470. Published online 2016 Aug 18. https://doi.org/10.1371/journal.pone.0161470 PMID: 27536777

44. Marques DS, Sandrini JZ, Boyle RT, Marins LF, Trindade GS. Relationships between multidrug resistance (MDR) and stem cell markers in human chronic myeloid leukemia cell lines. Leuk Res. 2010; 34:757–762. Epub 2009 Dec 6. https://doi.org/10.1016/j.leukres.2009.11.004 PMID: 19969351

45. Galmiberti S, Bucelli C, Arrigoni E, Baraté C, Grassi S, Ricci F, et al. The hOCT1 and ABCB1 polymorphisms do not influence the pharmacodynamics of nilotinib in chronic myeloid leukemia. Oncotarget. 2017; 8:88021–88033. eCollection 2017 Oct 20. https://doi.org/10.18632/oncotarget.21406 PMID: 29152138

46. Shen T, Kuang Y-H, Charles R, Ashby CR, Lei JY, Chen A, et al. Imatinib and Nilotinib Reverse Multidrug Resistance in Cancer Cells by Inhibiting the Efflux Activity of the MRP7 (ABCC10). PLoS One. 2009; 4: e7520. Published online 2009 Oct 20. Correction in: PLoS One. 2009; 4: https://doi.org/10.1371/journal.pone.0007520 PMID: 19841739

47. Lin H, Chen M, Rothe K, Lorenzi MV, Woolfson A, Jiang X. Selective JAK2/ABL dual inhibition therapy effectively eliminates TKI-insensitive CML stem/progenitor cells. Oncotarget. 2014; 5:8637–8650. https://doi.org/10.18632/oncotarget.2353 PMID: 25226617

48. Sloma I, Mitjavila-Garcia MT, Feraud O, Griselli F, Ouddhiri N, El Marsafy S, et al. Whole-genome analysis reveals unexpected dynamics of mutant subclone development in a patient with JAK2-V617F-positive chronic myeloid leukemia. Exp Hematol. 2017; 53:48–58. Epub 2017 Jun 8. https://doi.org/10.1016/j.exphem.2017.05.007 PMID: 28602946

49. Zhang X, Tu H, Yang Y, Wan Q, Fang L, Wu Q, Li J. High IL-7 levels in the bone marrow microenvironment mediate imatinib resistance and predict disease progression in chronic myeloid leukemia. Int J Hematol. 2016; 104:358–367. Epub 2016 Jun 6. https://doi.org/10.1007/s12185-016-2028-9 PMID: 27272942

50. Seif F, Khoshmirsaefa M, Aazami H, Mohsenzadegan M, Sedighi G, Bahar M. The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells. Cell Commun Signal. 2017; 15:23. Review. https://doi.org/10.1186/s12964-017-0177-y PMID: 28637459

51. Majaros A, Platanitis E, Kernbauer-Hözl E, Rosebrock F, Müller M, Decker T. Canonical and non-canonical aspects of JAK-STAT signaling: lessons from interferons for cytokine responses. Front Immunol. 2017; 8:29. https://doi.org/10.3389/fimmu.2017.00029 eCollection 2017.

52. Gu S, Sayad A, Chan G, Yang W, Lu Z, Virtanen C, et al. SHP2 is required for BCR-ABL1-induced hematologic neoplasia. Leukemia. 2018; 32:203–213. Epub 2017 Aug 14. https://doi.org/10.1038/leu.2017.250 PMID: 28804122
53. Samanta AK, Chakraborty SN, Wang Y, Kantarjian H, Sun X, Hood J, et al. Jak2 inhibition deactivates Lyn kinase through the SET-PP2A-SHP1 pathway, causing apoptosis in drug-resistant cells from chronic myelogenous leukemia patients. Oncogene. 2009; 28:1669–1681. Epub 2009 Feb 23. https://doi.org/10.1038/onc.2009.7 PMID: 19234487

54. Quentmeier H, Eberth S, Romani J, Zaborski M, Drexler HG. BCR-ABL1-independent PI3Kinase activation causing imatinib-resistance. J Hematol Oncol. 2011; 4:6. https://doi.org/10.1186/1756-8722-4-6 PMID: 21299849